SpaceX’s $60B Cursor Option

What I Read This Week: a summary of the content that I consumed this past week…

SpaceX said on April 21 that it secured an option to acquire Cursor, the AI coding startup, for $60B later this year, or pay $10B for a new partnership if the acquisition does not happen.

Cursor has become one of the leading AI coding products by turning the developer environment itself into an AI interface. The app sits closer to the work itself: where engineers write, test, debug, and increasingly delegate software tasks. It maintains a daily workflow used by high-value technical workers and creates a distribution channel through which model providers can compete for developer usage.

Cursor still sells access to Claude and GPT models even as Anthropic and OpenAI build their own coding products, which makes Cursor both a customer and a competitor to the frontier labs. And last month, two of Cursor’s most senior engineering leaders transitioned to xAI, where both report directly to Musk.

Reuters framed the deal as SpaceX’s deeper push into AI developer tools, while TechCrunch reported that Cursor had been preparing a $2B private fundraise at a $50B valuation, up massively from its $2.5B valuation last January.

SpaceX said the partnership would combine Cursor’s product and distribution with the Colossus training supercomputer, which is described as having the equivalent compute power of one million Nvidia H100 chips.

Both companies can find a win-win scenario where Cursor gets access to the massive amounts of compute that rivals the frontier labs, while xAI has a chance to break into the highly sought-after enterprise coding business with a SOTA model.

Nature published Sony AI’s Ace research on April 22, describing an autonomous table-tennis robot competitive with elite human players. The paper says Ace played under official International Table Tennis Federation rules against five elite players and two professional players. It won three of five matches against elite players and remained competitive in the others. Sony AI later reported additional post-submission matches in which Ace defeated elite and professional players.

The reason this matters is not that a robot can hit a ball. Robots have played simplified versions of table tennis for decades. The hard problem is real-time interaction against an adversarial human, with spin, speed, imperfect perception, and less than a second between shots.

Nature notes that table-tennis balls can exceed 20 meters per second in high-level games and reach spin rates of 1,000 radians per second. Ace addresses that problem through event-based vision sensors, model-free reinforcement learning, and high-speed robotic hardware. Its custom robot platform has eight degrees of freedom, designed to give the racket enough position, orientation, and velocity control for competitive play.

In software, an AI system can pause, sample, retry, and correct. In table tennis, the world keeps moving, and the system must perceive the ball, estimate spin, plan a return, move the racket, and adapt to a human opponent in real time.

Science published a Stanford-led paper this month showing some bacteria appear able to make DNA in a way researchers did not think life used. Normally, DNA is made by copying a template. One molecule pulls the two strands apart, and another builds a matching strand along each side. The result is two copies of the same DNA. But new research on how bacteria fight viruses shows that this rule has at least one exception.

In this case, the researchers found a bacterial system that can build part of a DNA sequence without following the usual script. It suggests biology may have more ways of making genetic material than experts have long assumed.

The discovery does not overturn modern genetics, nor does it mean that all life works this way. It seems to be a specialized trick used by bacteria, likely as part of their defense against viruses. But narrow exceptions can reshape science by revealing unknown mechanisms that researchers can now leverage. It opens a new chapter in bacterial immunity, and it gives synthetic biology a new enzyme architecture to study, even if practical engineering applications remain speculative.

All In: SpaceX-Cursor Deal, SaaS Debt Bomb, New Apple CEO, SPLC Indictment, Colon Cancer Spike